This is a Presidential Advisory Committe on HIV/AIDS (PACHA) and Centers for Disease Control and Prevention (CDC) /Health Resources and Services Administration (HRSA) Advisory Committee on HIV, Viral Hepatitis, and STD Prevention and Treatment (CHAC) resolution requesting the elimination of the ban on federal funding for the support of syringe access.

In recognition of National Hepatitis Awareness Month and May 19th National Hepatitis Testing Day, please join Senator Mazie K. Hirono for a briefing on hepatitis B and the elimination of perinatal transmission.

NVHR has created a fact sheet about The Viral Hepatitis Testing Act of 2014
(S. 2538). The legislation would authorize $80 million over three years for a comprehensive national system – an enhancement and strengthening of existing public health programs – for surveillance, education, testing, and linkage to care for HBV and HCV, to prevent transmission, morbidity, and mortality from viral hepatitis-related chronic liver disease and liver cancer.

NVHR has developed a fact sheet about The Viral Hepatitis Testing Act of 2013 (H.R. 3723). The legislation would authorize $80 million over three years for a comprehensive national system – an enhancement and strengthening of existing public health programs – for surveillance, education, testing, and linkage to care for HBV and HCV, to prevent transmission, morbidity, and mortality from viral hepatitis-related chronic liver disease and liver cancer.

People with chronic hepatitis C who are using methadone or buprenorphine to manage opiate addiction can be safely and effectively treated with AbbVie's 3D all-oral direct-acting antiviral regimen plus ribavirin, resulting in a 97% cure rate, according to a report this week at the 20th International AIDS Conference in Melbourne.

The hepatitis C virus (HCV) World Community Advisory Board (CAB) grew from an international AIDS activist movement. The objectives of the meeting were threefold:
To provide a forum for leading activists to learn about developments in HCV treatment and access barriers;
To find common advocacy strategies; and
To meet with pharmaceutical companies about their plans for low- and middle-income countries (LMICs).

The importance of integrating people who inject drugs into HCV treatment programs. Arguments from a public health and human rights perspective. This document develops core arguments for why it is relevant, feasible, and indeed crucial to include people who inject drugs in national treatment guidelines and programs for chronic HCV infection – from both public health and human rights perspectives.